Page 163 - Read Online
P. 163

Elhage et al. Plast Aesthet Res 2020;7:16  I  http://dx.doi.org/10.20517/2347-9264.2020.03                                             Page 3 of 9





                    Timing of injections At least 4 weeks prior to surgery At least 4 weeks prior to surgery 0-9 days prior to surgery (median 6 days)  2 weeks prior to surgery  1-2 weeks prior to surgery  4 weeks prior to surgery  2-4 weeks prior to surgery  4 weeks prior to surgery  3-4 weeks prior to surgery  4-6 weeks prior to surgery




























                    Injection sites 6 total, 3 sites bilaterally at EO, IO, and TA, 50 U/25 mL per site (16.6 units/8.3 mL per muscle) 6 total, 3 sites bilaterally at EO, IO, and TA, 50 U/25 mL per site (8 mL per muscle) 10 total, 5 sites bilaterally, 16.6 U/5 mL per site, divided between EO, IO, and TA* 6 total, 3 sites bilaterally at EO, IO, and TA, or 6 total, 3 sites bilerally at EO and IO 10 total, 5 sites bilaterally, 16.6 U/5 mL per site, divided between EO, IO, an





                      10 total, 5 sites bilaterally, 16.6 units per site* 10 total, 5 sites bilaterally between EO and IO, 16.6 U/5 mL per site*  6 total, 3 sites bilaterally at EO, IO, and TA  6 total, 3 sites bilaterally at EO and IO commonly published conversion ratio of 1:3 onabotulinum toxin A:abobotulinum toxin A to report the total BTA units used in each study [25] .  Ibarra-Hurtado et al. [14,16]  injected between the EO and IO in their 2013 study and did not spec













                 Table 1. Summary of botulinum toxin A treatment regimens

                    Total BTA units  166 units*  166 units*  300 units  300 units  200-300 units  166 units*  200 units  166 units*  300 units  200-300 units units of onabotulinum toxin A (Botox®) corresponds to the 500 units of abobotulinum toxin A (Dysport®) used in these studies





                    n  12  17  22  8  56  70  46  80  37  12

                    Year  2009  2014  2013  2016  2018  2018  2020  2019  2020  2020



                      Ibarra-Hurtado et al. [14]  Ibarra-Hurtado et al. [16]  Zendejas et al. [17]  Farooque et al. [18]  Rodriguez-Acevedo et al. [19]  Bueno-Lledó et al. [20]  Elstner et al. [22]  Bueno-Lledó et al. [21]  Nielsen et al. [23]  RESULTS Botulinum toxin A regimens  Botulinum toxin A efficacy  recurrences.





                    Ref.                  Chan et al. [24]
   158   159   160   161   162   163   164   165   166   167   168